2021
Cancer Immunology and the Evolution of Immunotherapy
Nurieva R, Divenko M, Kim S. Cancer Immunology and the Evolution of Immunotherapy. 2021, 3-29. DOI: 10.1007/978-3-030-56824-5_1.Peer-Reviewed Original ResearchDevelopment of cancer immunotherapeuticsHost anti-tumor immunityCancer immunotherapy modalitiesEvolution of immunotherapyAnti-tumor immunityHost immune cellsImmunotherapy modalitiesCancer immunotherapyCancer immunotherapeuticsCancer immunologyImmune cellsTumor cellsCellular mechanisms of interactionCancer cellsCancerCellular mechanismsImmunotherapyCellsImmunotherapeuticsTumorImmunityImmunologyFDAModalitiesTrials
2020
Optimizing Care for Patients With Adverse Events From Immunotherapeutics.
Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. The Cancer Journal 2020, 26: 537-542. PMID: 33298725, DOI: 10.1097/ppo.0000000000000492.BooksConceptsImmune checkpoint inhibitorsAdverse eventsCheckpoint inhibitorsImmune therapyGuideline-driven managementMajority of irAEsSteroid-refractory casesRisk patientsOptimal carePredictive biomarkersTumor boardIrAEsWellness clinicPatientsEarly detectionTranslational researchTherapyCareCommon occurrenceInhibitorsImmunotherapeuticsClinicSteroidsImmuneBiomarkers
2019
Synthetic Rhamnose Glycopolymer Cell-Surface Receptor for Endogenous Antibody Recruitment
De Coen R, Nuhn L, Perera C, Arista-Romero M, Risseeuw M, Freyn A, Nachbagauer R, Albertazzi L, Van Calenbergh S, Spiegel D, Peterson B, De Geest B. Synthetic Rhamnose Glycopolymer Cell-Surface Receptor for Endogenous Antibody Recruitment. Biomacromolecules 2019, 21: 793-802. PMID: 31829561, DOI: 10.1021/acs.biomac.9b01483.Peer-Reviewed Original ResearchConceptsImmune systemAntibody-mediated effector functionsTarget cell surfaceHuman serumEffector functionsCell surface membraneCell surface receptorsTarget cellsMonoclonal antibodiesAntibodiesAntibody recruitmentImmunotherapeuticsSmall molecule compoundsSerumCell surfaceLipophilic end groupsEnd groups
2017
Neutralization of Pathogenic Fungi with Small‐Molecule Immunotherapeutics
Chirkin E, Muthusamy V, Mann P, Roemer T, Nantermet PG, Spiegel DA. Neutralization of Pathogenic Fungi with Small‐Molecule Immunotherapeutics. Angewandte Chemie International Edition 2017, 56: 13036-13040. PMID: 28793176, DOI: 10.1002/anie.201707536.Peer-Reviewed Original ResearchConceptsImportant public health concernNovel therapeutic approachesHuman immune cellsSystemic fungal infectionsPublic health concernAntibody-recruiting moleculesFungal illnessImmune cellsNew antifungal agentsTreatment strategiesTherapeutic approachesEndogenous antibodiesRelevant functional assaysFungal infectionsHealth concernFunctional assaysAntifungal agentsNon-peptidic small moleculesC. albicans cellsCandida albicansCellsBiological evaluationAlbicans cellsImmunotherapeuticsIllnessNeutralization of Pathogenic Fungi with Small‐Molecule Immunotherapeutics
Chirkin E, Muthusamy V, Mann P, Roemer T, Nantermet P, Spiegel D. Neutralization of Pathogenic Fungi with Small‐Molecule Immunotherapeutics. Angewandte Chemie 2017, 129: 13216-13220. DOI: 10.1002/ange.201707536.Peer-Reviewed Original ResearchImportant public health concernNovel therapeutic approachesHuman immune cellsSystemic fungal infectionsPublic health concernAntibody-recruiting moleculesFungal illnessImmune cellsNew antifungal agentsTreatment strategiesTherapeutic approachesEndogenous antibodiesRelevant functional assaysFungal infectionsHealth concernFunctional assaysAntifungal agentsNon-peptidic small moleculesC. albicans cellsCandida albicansCellsBiological evaluationAlbicans cellsImmunotherapeuticsIllness
2016
Corrigendum to “Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics” [Curr. Opin. Pharmacol. 30 (2016) 93–105]
Chang K, Liu M. Corrigendum to “Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics” [Curr. Opin. Pharmacol. 30 (2016) 93–105]. Current Opinion In Pharmacology 2016, 30: 158-159. PMID: 27707534, DOI: 10.1016/j.coph.2016.09.005.Peer-Reviewed Original ResearchPD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
Gettinger S, Politi K. PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? Clinical Cancer Research 2016, 22: 4539-4541. PMID: 27470969, PMCID: PMC5653962, DOI: 10.1158/1078-0432.ccr-16-1401.Peer-Reviewed Original ResearchConceptsLung cancerNon-small cell lung cancerCell lung cancerCancer immunotherapeuticsEGFR mutantsCancerImmunotherapeuticsALKChronic hepatitis B: immune pathogenesis and emerging immunotherapeutics
Chang K, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Current Opinion In Pharmacology 2016, 30: 93-105. PMID: 27570126, DOI: 10.1016/j.coph.2016.07.013.Peer-Reviewed Original ResearchConceptsImmune modulatory approachesChronic hepatitis B.Chronic viral infectionsHost immune componentsImmune pathogenesisHBV infectionFunctional cureHepatitis BHepatitis B.Tumor immunotherapyModulatory approachesImmune componentsImmune interactionsClinical developmentViral infectionDisease pathogenesisNatural historyPathogenic responsesAspects of hostImmunotherapeuticsPathogenesisTumor therapyInfectionImmunotherapyTherapyRe‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase Receptor
Rullo A, Fitzgerald K, Muthusamy V, Liu M, Yuan C, Huang M, Kim M, Cho A, Spiegel D. Re‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase Receptor. Angewandte Chemie 2016, 128: 3706-3710. DOI: 10.1002/ange.201510866.Peer-Reviewed Original ResearchAntibody-recruiting small moleculeUrokinase-type plasminogen activator receptorMetastatic cancerPlasminogen activator receptorAntibody-recruiting moleculesCancer cell surface markersCell surface markersImmune responseNon-peptide ligandsTumor growthActivator receptorWeight lossCancer cellsCancerAgent doxorubicinUrokinase receptorReceptorsImmunotherapeuticsSmall moleculesSelective strategy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply